Quest Partners LLC Buys Shares of 926 Vaxcyte, Inc. (NASDAQ:PCVX)

Quest Partners LLC purchased a new position in shares of Vaxcyte, Inc. (NASDAQ:PCVX) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 926 shares of the company’s stock, valued at approximately $70,000.

A number of other institutional investors have also modified their holdings of PCVX. Principal Financial Group Inc. lifted its stake in Vaxcyte by 1.7% during the 4th quarter. Principal Financial Group Inc. now owns 22,008 shares of the company’s stock worth $1,382,000 after acquiring an additional 376 shares in the last quarter. Vanguard Personalized Indexing Management LLC purchased a new position in shares of Vaxcyte in the fourth quarter valued at approximately $208,000. Norges Bank acquired a new position in shares of Vaxcyte in the fourth quarter valued at approximately $57,494,000. PNC Financial Services Group Inc. increased its stake in Vaxcyte by 25.3% during the 4th quarter. PNC Financial Services Group Inc. now owns 6,986 shares of the company’s stock worth $439,000 after buying an additional 1,411 shares during the period. Finally, UBS Group AG increased its stake in Vaxcyte by 123.4% during the 4th quarter. UBS Group AG now owns 166,034 shares of the company’s stock worth $10,427,000 after buying an additional 91,729 shares during the period. 96.78% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have commented on PCVX shares. Mizuho boosted their price target on shares of Vaxcyte from $113.00 to $163.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 10th. Needham & Company LLC upped their price target on Vaxcyte from $95.00 to $140.00 and gave the stock a “buy” rating in a report on Tuesday, September 3rd. BTIG Research lifted their price objective on Vaxcyte from $98.00 to $160.00 and gave the company a “buy” rating in a research note on Tuesday, September 3rd. Bank of America boosted their price objective on Vaxcyte from $101.00 to $140.00 and gave the stock a “buy” rating in a research report on Wednesday, September 4th. Finally, Leerink Partners raised their target price on shares of Vaxcyte from $106.00 to $153.00 and gave the company an “outperform” rating in a report on Tuesday, September 3rd. Seven research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $147.50.

Insiders Place Their Bets

In other news, CEO Grant Pickering sold 15,000 shares of the business’s stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $75.64, for a total value of $1,134,600.00. Following the completion of the sale, the chief executive officer now directly owns 478,888 shares of the company’s stock, valued at approximately $36,223,088.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CEO Grant Pickering sold 15,000 shares of Vaxcyte stock in a transaction on Monday, June 24th. The shares were sold at an average price of $75.64, for a total value of $1,134,600.00. Following the transaction, the chief executive officer now directly owns 478,888 shares of the company’s stock, valued at approximately $36,223,088.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Andrew Guggenhime sold 8,000 shares of the company’s stock in a transaction on Thursday, July 18th. The shares were sold at an average price of $81.17, for a total transaction of $649,360.00. Following the completion of the sale, the chief financial officer now owns 96,720 shares of the company’s stock, valued at approximately $7,850,762.40. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 85,283 shares of company stock valued at $7,271,218. 3.10% of the stock is currently owned by insiders.

Vaxcyte Stock Performance

Shares of NASDAQ PCVX opened at $116.75 on Wednesday. The stock’s 50-day simple moving average is $87.05 and its 200-day simple moving average is $75.47. The firm has a market capitalization of $13.03 billion, a PE ratio of -27.28 and a beta of 0.97. Vaxcyte, Inc. has a fifty-two week low of $44.20 and a fifty-two week high of $119.50.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings data on Tuesday, August 6th. The company reported ($1.10) earnings per share for the quarter, topping the consensus estimate of ($1.14) by $0.04. During the same quarter in the previous year, the company posted ($0.70) EPS. On average, sell-side analysts forecast that Vaxcyte, Inc. will post -4.33 earnings per share for the current fiscal year.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.